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doses up to 100 mg per day with second drug therapy of 
azathioprine or alternatively cyclophosphamide. After 
the transfer to our hospital a plethora of laboratory 
studies for rheumatologic, inflammatory, and infectious 
processes where obtained and except for a very modest 
decrease in C4 all where normal. A further contrast 
enhanced MRT of the brain showed extensive right- 
sided white matter disease with significant extension into 
the left hemisphere. An HIV ELISA, a CD4 count, and 
a JC virus PCR were obtained.The ELISA was negative; 
but the CD4 count was 52 and JCV-VL was 2888 
copies/ml (normal ~80). An exhaustive literature search 
revealed minimal therapeutic options for the JC virus 
infection, and the patient was discharge to hospice in the 
care of her physician on a suggested regimen of 
a prednisone taper, and hopefully therapeutic alpha- 
interferon and cidofovir treatment. As of February 2002 
the patient remains bed bound. 
This devastating case of JC virus infection illustrates 
the confounding diagnostic dilemmas frequently encoun- 
tered by practitioners. In this instance a consistent 
explanation is found with the realization that the patient 
probably suffers from advanced iatrogenic immuno- 
suppression and the resultant possible opportunistic in- 
fections. 
Valacyclovir for the prevention of CMV disease after 
renal transplantation: A 5year follow-up 
*Hans-H. Neumayer, Jean-Paul Squifflet, 
David Lowance, Christophe M. Legendre 
*Department of Nephrology, University Hospital 
Charit&, Berlin, Germany 
Objective: Valacyclovir 2g four times daily for 90 days 
has been shown (Lowance et al., NEJM 1999: 340:1462- 
70) to reduce the incidence of cytomegalovirus (CMV) 
infection and disease and acute graft rejection (GR) at 
six months vs placebo after renal transplantation. Among 
the CMV seropositive patients (R+) the incidence of 
CMV disease was reduced from 6% to 1% and there was 
a reduction in biopsy confirmed acute GR from 36% 
to 30%. CMV disease was significantly reduced in the 
donor-positive recipient-negative (D+R-) group from 
45% to 16% and rate of biopsy confirmed acute GR 
from 52% to 26% compared to placebo. This retro- 
spective review of patients’ medical notes was designed 
to assess whether the benefits extend to increased graft 
function and survival during 5 years follow-up. 
Methods: Data were available for 449 of the 616 patients 
enrolled in the original study, P66/H73-012. The primary 
population for analysis was the ITT population of all 
patients randomised in the original study. The primary 
endpoint was time to allograft failure up to 5 years post- 
transplant. Rates of acute GR, chronic GR, CMV disease 
and survival were secondary endpoints. 
Results: No significant treatment difference was 
observed for time to allograft failure in either the R+ or 
D+R- patients although the benefits in preventing 
CMV disease and acute GR are still evident at 5 years. 
fR+) (D+R-J 
Val PBO Val PBO 
Endpoint n=204 n=204 HR n=106 n=l02 HR 
Allograft failure 28 23 1.29 25 24 0.91 
Acute GRa 39 41 0.91 36 55 0.52* 
Chronic GRa 28 16 1.86** 24 30 0.67 
fvavkeaseb 2 8 11 6 0.28* 6  15 7 43 16 0.22* .43 
*Statistically significant in favour of valaciclovir. **Statistically significant 
in favour of placebo. 
aBiopsy confirmed graft rejection. bLaboratory confirmed graft rejection. 
Conclusions: The benefit of 90 days treatment with 
valacyclovir in preventing acute GR in D+R- patients 
is still apparent at 5 years post-transplant. A trend to 
increased patient survival with valacyclovir in the high- 
risk D+R- patients is noted. 
Diagnostic and prognostic value of nested polymerase 
chain reaction in the post-transplant reactivation of 
cytomegalovirus (CMV) infection 
Sarman Singh, Niti Singh, R. Sivakumar 
Department of Laboratory Medicine, All India Institute 
of Medical Sciences, New Delhi (India) 
Confirmatory diagnosis of reactivated human cyto- 
megalovirus (HCMV) infections can only be made by 
culturing the virus in cell culture, or alternatively by 
detecting its antigen or its nucleic acids using amplifica- 
tion techniques. It is necessary because presence of IgM 
antibodies is not a reliable method of viral replication 
and does not correlate well with disease manifestations. 
Detection of HCMV DNA in clinical specimens is 
considered a cornerstone in the diagnosis of CMV 
disease. For amplifying the specific CMV DNA nested 
polymerase chain reaction (nPCR) is reported to higher 
specificity. Therefore, we carried out a study to compare 
the usefulness of nested PCR vis-a-vis commonly used 
u-capture enzyme linked immunosorbent assay (mac- 
ELISA) in renal and bone marrow transplant patients 
with clinical manifestations suggestive of post-transplant 
CMV reactivation. A total of 49 blood specimens were 
collected from 19-bone marrow and 30 renal transplant 
patients. All the samples were subjected to IgG, IgM 
ELISA and Nested PCR assay. The age of our patients 
ranged from 18 to 50 years (mean age 32+17). Most of 
our patients were males (44) while only 5 were females. 
All of the 49 patients were found positive for anti-CMV 
IgG antibodies (100%) and only 22.45% were IgM 
positive. Where as, nPCR was positive in 69.38% of 
cases. All PCR positive patients responded to anti-CMV 
therapy. Hence, this study concluded that the nested 
PCR is more sensitive as well as specific in symptomatic 
transplant cases and must be carried out at all transplant 
